Adipose derived autologous mesenchymal stem cell therapy (Celltex Therapeutics)

Adipose-derived mesenchymal stem cells (ADMSCs) are being increasingly explored in regenerative medicine because of their accessibility and potent immunomodulatory properties. Their application is gaining traction in gastroenterology, where inflammation and tissue degeneration are central to disease progression.

This review aims to provide an in-depth overview of the biological mechanisms, therapeutic effects, and clinical applications of ADMSCs, focusing on gastrointestinal disorders. We conducted a narrative literature review of relevant studies in PubMed, Google Scholar, and Scopus, covering key findings from gastroenterology, cardiology, neurology, orthopedics, and plastic surgery (editor comment#4b). Original studies evaluating ADMSCs use in gastroenterology and related medical fields were included. Data were organized to illustrate the cellular pathways, cytokine profiles, and paracrine signaling mechanisms through which ADMSCs exert therapeutic effects. ADMSCs consistently reduced inflammation, enhanced tissue repair, and modulated immune responses.

In gastroenterology, ADMSCs have demonstrated potential in the treatment of inflammatory bowel disease and liver disorders by promoting mucosal healing and limiting fibrosis. They hold significant promise because of their robust immunomodulatory and regenerative properties. Future studies should focus on refining the isolation methods, validating therapeutic protocols, and establishing safety and efficacy through controlled trials to bring ADMSCs into clinical practice.

Objective : Radiotherapy is a key treatment for brain tumors and arteriovenous malformations; however, it is associated with adverse effects such as brain edema, demyelination, and delayed necrosis. These adverse effects are driven by inflammation and apoptosis, initiated by cytokines such as tumor necrosis factor-α, transforming growth factor, and interleukin-1β. Adipose tissuederived mesenchymal stromal cells (ADMSCs) offer protection against radiation-induced damage owing to their pluripotency and antiinflammatory properties. In this study, we investigated the neuroprotective effects of ADMSCs on irradiated brain cells.Methods : Rat cortical neurons, human glioblastoma cells (U87 cell line), and ADMSCs were exposed to radiation doses ranging from 3 Gy to 40 Gy. Co-cultures of irradiated neurons with ADMSCs or their secretomes were assessed for apoptotic and inflammatory markers. Cell viability was measured using lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Apoptosis was determined by using Hoechst staining and western blot analysis of proteins such as Bax, caspase-3, and Bcl-2.Results : Higher radiation doses (30–40 Gy) significantly increased apoptosis and decreased the viability of cortical neurons and U87 cells. Co-culture with ADMSCs reduced the levels of apoptosis markers, particularly Bax and cleaved caspase-3, and promoted cell survival. Direct co-culture provided more pronounced protection than did ADMSC secretome treatment, suggesting that cell-to-cell interactions are crucial for neuroprotection.Conclusion : ADMSCs have a significant potential for mitigating radiation-induced brain damage by reducing apoptosis and inflammation. Direct ADMSC co-culture outperformed secretome treatment, thereby emphasizing the importance of physical cell interactions. ADMSC therapy may be a promising approach to protect against radiotherapy-induced neural damage. Further studies are required to optimize the delivery and timing of stem cell therapy.